Literature DB >> 28839996

Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015.

Pingli Wang1, Jixia Zou1, Jingni Wu1, Chengyan Zhang1, Chengxi Ma1, Juan Yu1, You Zhou1, Baizhou Li2, Kai Wang1.   

Abstract

BACKGROUND: More than one-third of lung cancer worldwide occurring in China. However, the clinical profiles of lung cancer patients in the mainland of China are rarely reported and largely unknown. The objective of this study is to analyze the characteristics and time trends of newly diagnosed lung cancer cases during the past 5 years in East China.
METHODS: The data came from an academic tertiary care hospital of East China. Patients who were newly diagnosed as lung cancer from 2011 to 2015 were enrolled. All new cases got pathological supports by lung biopsy or surgery. Tumor staging was performed according to the seventh edition of the tumor node metastasis (TNM) classification of malignant tumors. The patients' disease information was collected from the database of the hospital information system (HIS).
RESULTS: From 2011 to 2015, aggregately 5,779 patients, including 3,719 males and 2,060 females, were diagnosed as lung cancer. The major histologic subtypes of lung cancer were adenocarcinoma (ADC, 60.0%), squamous cell carcinoma (SCC, 25.6%), small cell lung cancer (SCLC, 8.5%), large cell carcinoma (0.6%), adenosquamous carcinoma (1%), other non-small cell carcinoma (1.6%) and unclassified or rare carcinoma (2.8%). ADC proportion of female was much higher than that of male. A higher proportion of advanced stage (stage IIIB, IV) of lung cancer existed in patients who were admitted to hospital due to respiratory or cancer related symptoms (RCRS) than those without RCRS. Smoking rate in male patients reached 80.2%, while it was only 2.7% in females. EGFR mutation existed in 66% of female and 37% of male patients with ADC.
CONCLUSIONS: This study demonstrates the clinicopathologic characteristics of lung cancer patients from East China, including histologic composition, staging proportion, smoking prevalence and gene mutation status. During the past 5 years, the proportion of ADC has increased gradually whereas SCC decreased.

Entities:  

Keywords:  China; Lung cancer; profiles

Year:  2017        PMID: 28839996      PMCID: PMC5542980          DOI: 10.21037/jtd.2017.06.102

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

Review 1.  Epigenetic mechanisms and cancer: an interface between the environment and the genome.

Authors:  Zdenko Herceg; Thomas Vaissière
Journal:  Epigenetics       Date:  2011-07       Impact factor: 4.528

Review 2.  Lung cancer in China: challenges and interventions.

Authors:  Jun She; Ping Yang; Qunying Hong; Chunxue Bai
Journal:  Chest       Date:  2013-04       Impact factor: 9.410

3.  Influence of sex on lung cancer histology, stage, and survival in a midwestern United States tumor registry.

Authors:  Geoffrey Ringer; J Michael Smith; Amy M Engel; Mary Pat Hendy; Janet Lang
Journal:  Clin Lung Cancer       Date:  2005-11       Impact factor: 4.785

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study.

Authors:  Martin Reck; Koichi Hagiwara; Baohui Han; Sergei Tjulandin; Christian Grohé; Takashi Yokoi; Alessandro Morabito; Silvia Novello; Edurne Arriola; Olivier Molinier; Rose McCormack; Marianne Ratcliffe; Nicola Normanno
Journal:  J Thorac Oncol       Date:  2016-07-25       Impact factor: 15.609

6.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

7.  Histological subtypes of lung cancer in Chinese women from 2000 to 2012.

Authors:  Xiao Nong Zou; Dongmei Lin; Ann Chao; Xia Wan; Qinfu Feng; Junling Li; Jie Yang; Gong Huan Yang; Ning Lv
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

8.  Lung cancer in Hong Kong Chinese: mortality and histological types, 1973-1982.

Authors:  I T Kung; K F So; T H Lam
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

9.  Histological typing of lung cancers in Hong Kong.

Authors:  S H LEE; T O TS'O
Journal:  Br J Cancer       Date:  1963-03       Impact factor: 7.640

10.  Trends in lung cancer incidence by histological type in Osaka, Japan.

Authors:  Yasuhiro Toyoda; Tomio Nakayama; Akiko Ioka; Hideaki Tsukuma
Journal:  Jpn J Clin Oncol       Date:  2008-08-09       Impact factor: 3.019

View more
  5 in total

1.  Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China.

Authors:  Haijing Guan; Chunping Wang; Chen Chen; Sheng Han; Zhigang Zhao
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

2.  Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese Oncologists.

Authors:  Chang Xu; Meng Li; Xuwei Cai; Shuanghu Yuan; Jianzhong Cao; Shuchai Zhu; Ming Chen; Nan Bi; Xiao Hu; Jiancheng Li; Wei Zhou; Ping Wang; Lujun Zhao; Ningbo Liu
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

3.  Analysis of the clinicopathological characteristics and their trends among patients with lung cancer undergoing surgery in a tertiary cancer hospital of north China during 2000-2013.

Authors:  Xinqiang Ji; Yun Fang; Jing Liu
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 4.  Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.

Authors:  Anwen Xiong; Jiali Wang; Caicun Zhou
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

Review 5.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.